Experimental oncology最新文献

{"title":"MINIMAL RESPIRATORY MOTION OF THE BREAST IN FREE BREATHING: A 4D CT NARRATIVE VIDEO REVIEW.","authors":"V Vinh-Hung, O Gorobets, W Kao, T Gevaert, G Storme, G D'Amato, N P Nguyen, M De Ridder","doi":"10.15407/exp-oncology.2026.02.108","DOIUrl":"10.15407/exp-oncology.2026.02.108","url":null,"abstract":"<p><p>Respiratory motion is a concern in radiotherapy of most sites, including breast cancer. Conventional radiation treatment planning routinely increases the margins around breast target volumes to account for motion. However, few studies have quantified the actual extent of respiratory motion during free breathing. A review of publicly available four-dimensional computed tomography (4D CT) video data was conducted to estimate the preponderance of breast respiratory motion. Selected videos were those containing sequences displaying movement of the breast/chest wall. Images were visually categorized as showing minimal motion if movements were estimated as ≤ 3 mm, moderate if about 5 mm, and substantial if about 10 mm or more. Respiratory motion of the breast/chest wall was minimal in 22 of the 38 cases (57.9%), moderate in 12 cases (31.6%), and substantial in 4 cases (10.5%). In line with emerging surface-guided data, this video review shows the frequent observation of minimal respiratory motion of the breast/chest wall. These findings question whether routine respiratory-motion-based target expansion is necessary in all patients.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"48 2","pages":"108-119"},"PeriodicalIF":0.0,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"STUDY OF PREDICTIVE VALUE OF RAD51 EXPRESSION FOR THE EFFECTIVENESS OF PLATINUM-BASED THERAPY OF HIGH-GRADE SEROUS OVARIAN CARCINOMA.","authors":"P Gordiichuk, M Doronina, O Ponomarova, M Gordiichuk, D Shapochka, D Melnyk, A Tereshchenko","doi":"10.15407/exp-oncology.2026.02.133","DOIUrl":"10.15407/exp-oncology.2026.02.133","url":null,"abstract":"<p><strong>Background: </strong>The search for novel markers of predictive significance is an important issue in the management of ovarian cancer (OC) patients. Recently, the expression of the RAD51 protein, involved in homologous DNA repair has been shown to be predictive of platinum chemotherapy response in OC patients.</p><p><strong>Aim: </strong>To establish the relationship between the level of RAD51 protein expression in patients with high-grade serous ovarian carcinoma (SOC) after neoadjuvant platinum chemotherapy and the frequency of recurrence, disease progression, and relapse-free survival.</p><p><strong>Materials and methods: </strong>RAD51 status was assessed in the archival histological material of 30 patients with SOC of stage III who received perioperative platinum-based chemotherapy. RAD51 expression was analyzed using a double-staining technique in samples containing at least 100 geminin-positive tumor cells. RAD51 status was considered positive if > 10% of geminin-positive nuclei were positive for RAD51.</p><p><strong>Results: </strong>In 16 of 30 cases, the tumor had a RAD51-positive status (homologous repair proficient, HRP), and in 14 - RAD51-negative (homologous repair deficient, HRD). We found that the risk of disease progression in patients with RAD51 HRP status was 3.42 times higher compared to patients with RAD51 HRD status (HR = 3.42; 95% CI 1.38-8.46; p = 0.008). In SOC patients with RAD51 HRP status, a significantly higher (p < 0.001) rate of disease progression over 3 to 12 months of postoperative observation compared to patients with RAD51 HRD status was detected.</p><p><strong>Conclusions: </strong>RAD51 expression is predictive for the response of highgrade SOC to platinum therapy.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"48 2","pages":"133-138"},"PeriodicalIF":0.0,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SULFORAPHANE SUPPRESSES HEPATOCELLULAR CARCINOMA IN MICE VIA ACTIVATING p53, MITIGATING OXIDATIVE STRESS, AND INHIBITING ANGIOGENESIS.","authors":"Kholoud A Omran, Yomna I Mahmoud, Asmaa A Mahmoud, Nagui H Fares","doi":"10.15407/exp-oncology.2026.02.120","DOIUrl":"10.15407/exp-oncology.2026.02.120","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. Sulforaphane (SF) is a natural isothiocyanate that exhibits anticarcinogenic activity against various cancer cells in vivo and in vitro, with no observed side effects. It also has a prophylactic effect against early stages of some cancer models, including HCC. The study aimed to assess the therapeutic anticarcinogenic effect of SF in experimental murine HCC in vivo and to estimate possible underlying mechanisms of its effects on cell proliferation, angiogenesis, and antioxidant status.</p><p><strong>Materials and methods: </strong>HCC was induced in mice by a single intraperitoneal dose of 100 mg/kg of diethylnitrosamine, followed by 22 weekly intraperitoneal doses of 0.5 mg/kg of carbon tetrachloride. After the induction of HCC, SF (2 mg/kg body weight) was given orally from weeks 25 to 28. Then we conducted histopathological examination, biochemical analysis of blood sera, and immunohistochemical analysis of marker expression in liver sections.</p><p><strong>Results: </strong>SF improved liver structure and function in HCC-bearing mice and survival rate, significantly reduced the expression of tumor marker alpha-fetoprotein and the number of hepatic nodules, and downstaged HCC. These changes were accompanied by an increase in total antioxidant capacity, expression of p53 and Bax, as well as a significant decrease in lipid peroxidation and immunoreactivity of PCNA, VEGF, and Bcl-2 in liver tissues.</p><p><strong>Conclusion: </strong>SF decreased the number of tumor nodules and ameliorated HCC by activating p53 expression, inducing apoptosis, and inhibiting proliferation, oxidative stress, and angiogenesis. These findings support further translational evaluation of SF as a potential therapeutic agent for HCC.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"48 2","pages":"120-132"},"PeriodicalIF":0.0,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"THERAPEUTIC ROLE OF siRNA IN GASTRIC CANCER: GENE SILENCING MECHANISMS AND NANOCARRIER-BASED DELIVERY STRATEGIES.","authors":"Gheysar Seifollahnezhad, Berrin Erdağ","doi":"10.15407/exp-oncology.2026.02.081","DOIUrl":"10.15407/exp-oncology.2026.02.081","url":null,"abstract":"<p><p>Gastric cancer (GC) continues to be a significant global contributor to cancer-related mortality, primarily due to late-stage diagnoses, tumor heterogeneity, and the frequent emergence of therapeutic resistance. Despite advancements in surgical techniques, chemotherapy, targeted therapies, and immunotherapy, long-term survival rates remain unsatisfactory, underscoring the need for innovative, molecularly driven approaches. SiRNA has emerged as a promising gene-silencing tool capable of selectively downregulating oncogenic drivers and pathways associated with resistance via RNA interference. Preclinical studies using GC models demonstrate promising biological activity following siRNA-mediated suppression of various molecular targets - including CD44v6, Rac1, and ZNRD1-leading to reduced cell proliferation, inhibited migration and invasion, enhanced apoptosis, and increased chemosensitivity. However, the successful translation of siRNA-based strategies into clinical practice is fundamentally reliant on the development of efficient and safe delivery systems. Recent advancements in nanotechnology have enabled the development of multifunctional nanocarriers, including lipid-based nanoparticles, peptide-based systems, chitosanderived platforms, exosome-mimetic vesicles, layer-by-layer architectures, and stimuli-responsive theranostic nanoparticles. These engineered platforms are designed to enhance siRNA stability, improve tumor targeting, facilitate intracellular trafficking, and promote endosomal escape while minimizing off-target effects and immune activation. Preclinical findings suggest significant biological potential; however, additional research is required to address issues concerning biodistribution, safety, scalability, and regulatory standardization before clinical application. Overall, siRNA-based strategies may play a crucial role in the future development of precision-oriented therapeutic frameworks in GC research. Importantly, this review emphasizes the integration of molecular target selection with delivery system design in a GC-specific context. By systematically linking validated siRNA targets with corresponding nanocarrier strategies, this work provides a more application-oriented and translationally relevant perspective that is not typically addressed in conventional RNA interference or nanocarrier-focused reviews.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"48 2","pages":"81-97"},"PeriodicalIF":0.0,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EXPRESSION PATTERNS AND CLINICAL SIGNIFICANCE OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR, AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2/neu IN GALLBLADDER CANCER.","authors":"Deepti Mishra, Akhilesh Krishna, Priyanka Sameer, Shreshtha Ghosh, Durgesh Kumar, Ankur Verma","doi":"10.15407/exp-oncology.2026.02.139","DOIUrl":"10.15407/exp-oncology.2026.02.139","url":null,"abstract":"<p><strong>Background: </strong>Gallbladder carcinoma (GBC) is a rare cancer. However, it is the most common malignancy of the biliary tract system and ranks as the sixth most common malignancy of the digestive tract. It occurs primarily in females, and previous reports indicate that the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2/neu (HER2/neu) play significant roles in GBC. However, reported findings remain inconsistent. This study aimed to determine the expression status of ERα, ERβ, PR, and HER2/neu in GBC and to investigate their associations with clinicopathological features of patients.</p><p><strong>Materials and methods: </strong>55 GBC patients were included in the study. The expression levels of ERα, ERβ, PR, and HER2/neu proteins were evaluated using immunohistochemistry method.</p><p><strong>Results: </strong>ERα expression was absent in all cases, while PR and HER2/neu positivity were observed in 5.5% and 18.2% cases, respectively. Of total, 34 (61.8%) cases showed positive expression of ERβ. Compared with adjacent normal tissues, ERβ mean positivity was higher in GBC tissues. Significant associations were found between ERβ expression and tumor differentiation and gallstones (p < 0.05). Predominant expression of ERβ was observed in GBC of stages II and III.</p><p><strong>Conclusion: </strong>ERβ was frequently expressed in GBC and significantly associated with tumor differentiation, suggesting its potential role in progression of GBC.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"48 2","pages":"139-145"},"PeriodicalIF":0.0,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PHENOTYPIC SHIFT OF ADENOCARCINOMA TO SQUAMOUS CELL CARCINOMA OF RECTUM AFTER NEOADJUVANT CHEMORADIOTHERAPY WITH DETECTION OF HPV16: A CLINICAL CASE.","authors":"O Kovalyov, S Zavhorodniy, O Tolok, A Anenko, M Kubrak, M Danilyuk, K Kovalyov","doi":"10.15407/exp-oncology.2026.02.172","DOIUrl":"10.15407/exp-oncology.2026.02.172","url":null,"abstract":"<p><p>Adenosquamous carcinoma and pure squamous cell carcinoma (SCC) of the rectum are extremely rare malignancies, accounting for approximately 0.15% of all colorectal cancers. Increasing attention has been paid to tumor phenotypic plasticity in the context of intensive anticancer therapy. We report the case of a 45-year-old patient with locally advanced rectal adenocarcinoma (cT4bN2M0) who underwent total neoadjuvant therapy consisting of XELOX chemotherapy combined with pelvic radiotherapy. Baseline biopsy samples from multiple tumor areas showed moderately differentiated adenocarcinoma with an intestinal immunophenotype. After treatment, the resected tumor showed complete loss of intestinal differentiation markers (CK20, CDX2) and the emergence of a squamous immunophenotype with positive expression of p40 and p63. Histologically, the tumor was composed exclusively of poorly differentiated SCC. PCR analysis detected HPV16 DNA in the SCC component. Strong, diffuse p16INK4a expression was observed in both the primary adenocarcinoma and the post-treatment tumor. These findings indicate a marked therapy-associated phenotypic shift in tumor differentiation. However, the underlying biological mechanism remains uncertain. Possible explanations include therapy-associated tumor plasticity, clonal selection of a pre-existing squamous subclone, or an initially unrecognized mixed tumor phenotype. This case highlights the importance of careful pathological reassessment after neoadjuvant therapy in rectal cancer and illustrates the complexity of interpreting phenotypic changes in treated tumors. The potential role of HPV in such processes remains hypothetical and requires further investigation.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"48 2","pages":"172-180"},"PeriodicalIF":0.0,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DYNAMIC ANDROGEN RESPONSE INDEX AND ITS ASSOCIATION WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY FOLLOWING NEOADJUVANT ANDROGEN DEPRIVATION THERAPY.","authors":"Ye Afanasiev, S Vozianov, R Danylets, V Grygorenko, O Shulyak, M Sosnin, I Kholokharenko","doi":"10.15407/exp-oncology.2026.02.161","DOIUrl":"10.15407/exp-oncology.2026.02.161","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant androgen deprivation therapy (NADT) before radical prostatectomy (RP) remains controversial in the management of localized and locally advanced prostate cancer. A major limitation of this strategy is the lack of biomarkers capable of identifying tumors biologically sensitive to androgen deprivation. This study aimed to evaluate the prognostic value of a dynamic androgen response index (IAR) and develop a predictive model for biochemical recurrence (BCR) after RP.</p><p><strong>Materials and methods: </strong>The retrospective single-center study included 84 patients with prostate cancer treated with NADT followed by RP. The IAR was defined as the ratio between logarithmic slopes of PSA and testosterone decline during neoadjuvant therapy. Cox regression analysis was performed to identify predictors of BCR. A predictive model and nomogram were constructed based on independent predictors. Model performance was evaluated using ROC analysis, calibration plots, and decision curve analysis.</p><p><strong>Results: </strong>During a median follow-up of 56 months, BCR occurred in 62 patients. Clinical stage ≥ cT3a (HR 2.34; p = 0.003) and IAR (HR 1.48; p = 0.024) were independent predictors of BCR. The model demonstrated moderate discrimination (AUC 0.68) and satisfactory calibration.</p><p><strong>Conclusions: </strong>The IAR may reflect the biological responsiveness of prostate cancer to androgen deprivation. These findings should be considered hypothesis-generating and require further validation in the context of risk stratification for BCR following RP after NADT.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"48 2","pages":"161-171"},"PeriodicalIF":0.0,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SMOKING, ENVIRONMENTAL EXPOSURES, AND CHRONIC LUNG DISEASE AS KEY RISK FACTORS FOR LUNG CANCER IN NORTH SUMATRA.","authors":"Putri Aulia Anwar, Noni Novisari Soeroso, Setia Putra Tarigan, Putri Chairani Eyanoer","doi":"10.15407/exp-oncology.2026.02.152","DOIUrl":"10.15407/exp-oncology.2026.02.152","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer remains the leading cause of cancer mortality worldwide, with increasing incidence in many developing countries. Understanding region-specific risk factors is essential for effective prevention strategies. This study aimed to identify major determinants of lung cancer in North Sumatra, Indonesia.</p><p><strong>Materials and methods: </strong>A hospital-based observational study with a case-control analytical approach was conducted between August and November 2024 in three referral hospitals in North Sumatra. A total of 240 patients with histologically confirmed lung cancer and 240 controls without malignancy or chronic respiratory disease were included. Participants were comparable by sex and residential area, while age differences between groups were statistically adjusted in the multivariate regression model.</p><p><strong>Results: </strong>Smoking exposure differed significantly between cases and controls (p = 0.023). The multivariate analysis identified several independent predictors of lung cancer. Age <45 years increased the risk more than two-fold (OR 2.62; 95% CI 1.10-6.21), whereas age >65 years showed a lower relative risk (OR 0.54; 95% CI 0.33-0.88). The occupational exposure signicantly increased lung cancer risk (OR 1.91; 95% CI 1.13-3.25). Unhealthy indoor environments, characterized by poor ventilation and household pollutant exposure, were also associated with an increased risk (OR 2.53; 95% CI 1.45-4.40). Chronic respiratory diseases, particularly tuberculosis and chronic obstructive pulmonary disease, were more prevalent among cases and contributed to the elevated risk.</p><p><strong>Conclusions: </strong>Smoking exposure, occupational hazards, unhealthy indoor environments, and chronic pulmonary diseases are important determinants of lung cancer in North Sumatra. Public health strategies focusing on tobacco control, improved workplace safety, and reduction of indoor air pollution may substantially reduce lung cancer burden in this region.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"48 2","pages":"152-160"},"PeriodicalIF":0.0,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SURVIVAL PREDICTORS IN CANCER PATIENTS WITH BONE METASTASIS: RETROSPECTIVE COHORT SINGLE-CENTER STUDY.","authors":"M Vorobchuk, A Burlaka, A Diedkov","doi":"10.15407/exp-oncology.2026.02.146","DOIUrl":"10.15407/exp-oncology.2026.02.146","url":null,"abstract":"<p><strong>Background: </strong>Bone metastasis, a frequent complication in cancer patients, is associated with a significant decline in quality of life and reduced survival. Overall survival prognosis is critical for selecting the optimal treatment strategy, particularly for planning orthopedic surgery in patients with bone metastasis. The aim of the study was to delineate prognostic factors for overall survival in patients with bone metastasis following orthopedic surgery.</p><p><strong>Materials and methods: </strong>136 patients with bone metastasis treated at the National Cancer Institute (Ukraine) between 2006 and 2025 were included in a retrospective, single-center cohort study. The effects of the primary tumor type, number of metastases, presence of a pathologic fracture, prior treatment, and type of surgery on overall survival were assessed. Survival was analyzed using the Kaplan-Meier method, and the log-rank test was used for group comparisons. Multivariate Cox regression was used to identify independent prognostic factors.</p><p><strong>Results: </strong>The median overall survival was 32.8 months. Patients with solitary metastases had significantly better survival than those with multiple metastases (median 44.8 vs 18.4 months; p = 0.021). Pathologic fractures were associated with worse survival (median 25.4 vs 64.6 months; p = 0.014). In multivariate analysis, multiple metastases (HR 1.95; 95% CI 1.18-3.22; p = 0.009) and pathologic fractures (HR 1.82; 95% CI 1.05-3.17; p = 0.034) were identified as independent adverse factors. Combined treatment was associated with a lower risk of death (HR 0.48; 95% CI 0.26-0.91; p = 0.023). The type of surgery was not an independent factor affecting survival.</p><p><strong>Conclusion: </strong>The number of metastases and the presence of a pathologic fracture are key prognostic factors affecting survival in patients with bone metastasis. The results delineating prognostic factors in patients with bone metastasis may be useful for risk stratification and personalized treatment.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"48 2","pages":"146-151"},"PeriodicalIF":0.0,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MINIMAL RESIDUAL DISEASE ASSESSMENT IN ACUTE LYMPHOBLASTIC LEUKEMIA: METHODS FOR DETECTION AND QUANTIFICATION.","authors":"Sara Addakiri, Hanaa Bencharef, Asmaa Harrach, Samiha Jaddaoui, Khadija Ait-Ichou, Bouchra Oukkache","doi":"10.15407/exp-oncology.2026.02.098","DOIUrl":"10.15407/exp-oncology.2026.02.098","url":null,"abstract":"<p><p>Recently, the identification of minimal residual disease (MRD), also known as measurable residual disease, has seen significant advances driven by the evolving technological landscape in this field. Initially based on raw morphology, the field has since evolved to incorporate karyotyping, cytogenetics, flow cytometry, and other sensitive methods. This updated review discusses key technical considerations for successful MRD detection. We explore the correlation between the results obtained by flow cytometry and molecular genetic techniques.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"48 2","pages":"98-107"},"PeriodicalIF":0.0,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}